Related Experiment Videos
Adverse effects experienced by patients taking timolol
American Journal of Ophthalmology
|October 1, 1979
Abstract:
Adverse effects involving one or more organ systems occurred in 38 of 165 patients with various types of glaucoma when timolol was added to their glaucoma therapy. It was necessary to discontinue timolol because of these side effects in 15 (9%) of the patients. Double-masked studies will be necessary to clarify the relationship of these adverse effects to the use of timolol.
Insights
Adding timolol to glaucoma therapy caused adverse effects in 38 of 165 patients. Timolol was discontinued in 15 (9%) due to these side effects, necessitating further study.
Area of Science:
- Ophthalmology
- Clinical Pharmacology
Background:
- Glaucoma management often involves combination therapy.
- Timolol is a commonly used beta-blocker in glaucoma treatment.
Observation:
- Adverse effects were reported in 38 out of 165 patients (23%) receiving timolol as an addition to their glaucoma regimen.
- These effects impacted one or more organ systems.
Findings:
- Discontinuation of timolol was required for 15 patients (9%) due to the severity of adverse events.
- The specific relationship between timolol and these adverse effects requires further investigation.
Implications:
- Careful monitoring for systemic side effects is crucial when adding timolol to glaucoma treatment.
- Further double-masked studies are needed to confirm timolol's role in observed adverse events.